Articles tagged "Epstein-Barr virus (EBV)"

2020 American Transplant Congress
Long-Term Safety in Epstein-Barr Virus (EBV)-Seropositive Kidney-Only Transplant Recipients Treated with Belatacept (BELA) in Clinical Practice: Final Study Results from the ENLiST Registry
C. Larsen¹, F. Vincenti², T. Kou³, C. Shadur⁴, B. Bresnahan⁵, S. Jordan⁶, E. S. Woodle⁷, N. Goes⁸, J. Vella⁹, D. Wojciechowski¹⁰, M. Polinsky³, A. Gomez-Caminero³
¹Emory University Transplant Center, Atlanta, GA, ²UCSF Transplant Center, San Francisco, CA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Iowa Kidney Physicians, Des Moines, IA, ⁵Medical College of Wisconsin, Milwaukee, WI, ⁶Cedars-Sinai Medical Center, Los Angeles, CA, ⁷University of Cincinnati, Cincinnati, OH, ⁸Kaiser Permanente, San Francisco, CA, ⁹Maine Nephrology Associates, PA, Portland, ME, ¹⁰University Hospital Kidney and Liver Transplant Clinic, Dallas, TX
*Purpose: BELA, a selective T-cell costimulation blocker, is approved for the prophylaxis of organ rejection in EBV-seropositive adult kidney transplant recipients. In phase 3 BENEFIT…
2020 American Transplant Congress
Lifetime Survival Estimates Following Solid Organ Transplantation in the United States
C. Graham¹, M. Skeans², Y. Ahn², C. Watson³, A. Barlev⁴
¹RTI Health Solutions, Research Triangle Park, NC, ²Chronic Disease Research Group, Minneapolis, MN, ³Atara Biotherapeutics, South San Francisco, CA, ⁴Atara Biotherapeutics, Thousand Oaks, CA
*Purpose: The Scientific Registry of Transplant Recipients (SRTR) contains detailed patient and graft survival data for all solid organ transplants (SOT) in the United States…
2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
B. Shin, N. Ammerman, A. Vo, S. C. Jordan, M. Toyoda, S. Sethi
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
2020 American Transplant Congress
Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation
M. Yamada, A. Fukuda, M. Ogura, S. Shimizu, Y. Ishikawa, F. Kawano, H. Uchida, M. Takeda, Y. Yanagi, S. Sakamoto, M. Kasahara, K. Imadome
National Center for Child Health and Development, Tokyo, Japan
*Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…
2020 American Transplant Congress
Transplant Monitoring and PTLD Detection with B Cell Receptor Repertoire Analysis in a Large Prospective Pediatric Cohort
K. Jackson¹, O. Martinez², S. Krams², M. Robien³, M. Lapasaran², B. Armstrong⁴, C. Twist⁵, K. Weinberg⁶, D. Gratzinger¹, B. Tam¹, M. Sever⁴, M. Brown³, D. Bernstein⁶, C. Esquivel², S. D. Boyd¹
¹Department of Pathology, Stanford Univ School of Med, Stanford, CA, ²Department of Surgery/Division of Abdominal Transplantation, Stanford Univ School of Med, Stanford, CA, ³NIAID, NIH, Bethesda, MD, ⁴Rho, Chapel Hill, NC, ⁵Roswell Park, Buffalo, NY, ⁶Department of Pediatrics, Stanford Univ School of Med, Stanford, CA
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is a…
2020 American Transplant Congress
Patterns of Belatacept Use and Risk of Post-Transplant Lymphoproliferative Disorder (PTLD) in US Kidney Transplant Recipients – Analysis of Organ Procurement and Transplantation Network (OPTN) Database
W. S. Cherikh¹, T. Kou², J. Foutz¹, A. Gomez-Caminero²
¹United Network for Organ Sharing (UNOS), Richmond, VA, ²Bristol-Myers Squibb, Princeton, NJ
*Purpose: Belatacept, a selective T-cell costimulation blocker, was approved in 2011 for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients. PTLD…
2020 American Transplant Congress
Long-Term Outcomes of Patients with Epstein-barr Virus-Driven Post-Transplant Lymphoproliferative Disease Following Solid Organ Transplant or Allogeneic Hematopoietic Cell Transplant Treated with Tabelecleucel in an Expanded Access Program Study
S. Prockop¹, R. Reshaf², D. Tsai³, N. Bunin⁴, R. Abu-Arja⁵, K. Mahadeo⁶, W. Weng⁷, K. Van Besien⁸, D. Loeb⁹, S. Dwivedy Nasta¹⁰, E. Nemecek¹¹, M. Hiremath¹², S. Yue¹², Y. Sun¹², W. Navarro¹², S. Nikiforow¹³
¹Memorial Sloan Kettering Cancer Center, New York, NY, ²Columbia University Irving Medical Center, New York, NY, ³Loxo Oncology, Stamford, CT, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Nationwide Children's Hospital, Columbus, OH, ⁶MD Anderson Cancer Center, Houston, TX, ⁷Stanford University School of Medicine, California, CA, ⁸Weill Cornell Medical College, New York, NY, ⁹Children's Hospital at Montefiore, Bronx, NY, ¹⁰University of Pennsylvania, Philadelphia, PA, ¹¹Oregon Health & Science University, Portland, OR, ¹²Atara Biotherapeutics, New York, NY, ¹³Dana Farber Cancer Institute, Boston, MA
*Purpose: There is a need for effective, well‑tolerated therapies in pts who develop Epstein-Barr virus-driven post-transplant lymphoproliferative disease (EBV+ PTLD) after solid organ (SOT) or…
2019 American Transplant Congress
Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus
T. Ku, M. Cypel, R. V. Ribeiro, V. H. Ferreira, D. Kumar, A. Humar
UHN, Toronto, ON, Canada
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) can manifest as a B-cell malignancy associated with Epstein-Barr virus (EBV) infection. Risk of PTLD is greatest in EBV D+/R-…
2019 American Transplant Congress
Impact of Cytomegalovirus on the Immune System of Healthy Humans
W. Zhang, J. Robertson, G. Karadkhele, B. Johnson, C. Larsen
Emory Transplant Center, Emory University, Atlanta, GA
*Purpose: CMV is a frequent pathogen after transplantation. 2/3 of recipients harbor latent CMV and are at moderate risk. CMV- recipients divide into high or…